Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Abciximab · 1 trial · 1 indication
Sum STR was calculated as the difference between baseline (ECG I) and ECG III. The sum STR is the segment elevation resolution from all ECG leads associated with the infarct location. ST resolution, a method used to evaluate myocardial reperfusion, was expressed as a percentage of the baseline value (Complete: ≥ 70% resolution).
Sum STR was calculated as the difference between baseline (ECG I) and ECG III. The sum STR is the segment elevation resolution from all ECG leads associated with the infarct location. ST resolution, a method used to evaluate myocardial reperfusion, was expressed as a percentage of the baseline value (Complete: ≥ 70% resolution).
| Arm | Type | Description |
|---|---|---|
| Abciximab | ACTIVE_COMPARATOR | Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI. |
| Eptifibatide | EXPERIMENTAL | Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus. |
| Name | Type | Description |
|---|---|---|
| Abciximab | DRUG | Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI. |
| Eptifibatide | DRUG | Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus. |
Inclusion Criteria: * Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study. In cases of doubt a pregnancy test should be performed. (NB -post menopausal women currently recei...
Abciximab is used for myocardial infarction, specifically in the setting of primary percutaneous coronary intervention (PCI) for acute ST elevation myocardial infarction (STEMI). It is an investigational small molecule being studied in the cardiovascular therapeutic area.
Abciximab is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this drug for the treatment of myocardial infarction.
Abciximab is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed for this asset.
Abciximab has one completed Phase 3 trial, NCT00426751, titled 'Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)'. The trial enrolled 429 participants and was conducted in France and Germany.
No, Abciximab is not the same as eptifibatide. In the clinical trial NCT00426751, eptifibatide was used as an active comparator against abciximab to evaluate their relative efficacy in primary PCI for acute STEMI.